Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
NEWARK, Calif., Feb. 21, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 8th Annual Global Healthcare Conference in New York.
Event: Leerink Partners 8th Annual Global Healthcare Conference
Date: Thursday, Feb. 28
Time: 9:00 a.m. EST
Location: Lotte New York Palace Hotel
A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic for the potential treatment of anemia and iron overload related to rare blood diseases with an initial focus on beta thalassemia. PTG-200 is an oral peptide interleukin-23 receptor antagonist in development for the treatment of Crohn's disease. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the treatment of inflammatory bowel disease.
Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-leerink-partners-8th-annual-global-healthcare-conference-on-thursday-feb-28-300793324.html
SOURCE Protagonist Therapeutics, Inc.